次世代免疫療法の世界市場レポート 2025年

次世代免疫療法の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.1％で2,380億4,000万米ドルに成長します。予測期間中の成長は、がん罹患率の上昇、ヘルスケア支出の増加、キメラ抗原受容体（CAR）T細胞療法の採用拡大、慢性疾患の負担増、次世代医薬品の研究拡大などに起因すると考えられます。予測期間における主な動向としては、併用療法へのシフト、技術の進歩、治療アプローチの革新、個別化医療の進展、規制当局の支援強化などが挙げられます。

がん罹患率の増加が次世代免疫療法市場の拡大を牽引すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患群です。がんの罹患率の増加には、人口の高齢化、ライフスタイルの変化、環境暴露、検出方法の進歩など、いくつかの要因が関与しています。次世代免疫療法は、がんに対する身体の免疫反応を強化し、有効性、持続性、個別性を向上させる高度な標的治療を提供します。例えば、2024年5月、米国の政府機関である国立がん研究所（NCI）は、2022年に世界で約2,000万人が新たにがんに罹患し、970万人ががんに関連して死亡したと報告しました。2040年の予測では、2,990万人が新たにがんに罹患し、1,530万人ががんに関連して死亡すると推定されています。その結果、がんの有病率の上昇が次世代免疫療法市場の成長に拍車をかけています。

次世代免疫療法市場の主要企業は、がん、自己免疫疾患、感染症に対処するため、CAR T細胞療法などの革新的治療の開発に注力しています。CAR T細胞療法は、患者のT細胞（免疫細胞の一種）を遺伝子操作してキメラ抗原受容体（CAR）を発現させる先進的な免疫療法技術です。例えば、2025年1月、インドを拠点とする細胞・遺伝子治療の新興企業Immuneel Therapeutics Private Limitedは、インド初のCAR T細胞療法であるQartemiを発表しました。この治療は、がん細胞を認識して排除するように患者の免疫細胞を遺伝子改変することにより、成人B細胞性非ホジキンリンパ腫を標的とするもので、非常に効果的で個別化されたアプローチを提供します。この治療法は、従来の治療法では効果が得られなかった患者に新たな希望をもたらすものであり、国際的な同様の治療法よりも費用対効果が高いという利点もあります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界次世代免疫療法PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の次世代免疫療法市場：成長率分析
• 世界の次世代免疫療法市場の実績：規模と成長, 2019-2024
• 世界の次世代免疫療法市場の予測：規模と成長, 2024-2029, 2034F
• 世界次世代免疫療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の次世代免疫療法市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 抗体薬物複合体（ADC）
• アンジオテンシン変換酵素（ACE）阻害剤
• 免疫チェックポイント阻害剤
• 世界の次世代免疫療法市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 非経口
• 腫瘍内
• 皮下
• オーラル
• 世界の次世代免疫療法市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 臨床薬局
• その他の流通チャネル
• 世界の次世代免疫療法市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗PD-1抗体
• 抗PD-L1抗体
• 抗CTLA-4抗体
• 抗CD20抗体
• その他のモノクローナル抗体
• 世界の次世代免疫療法市場抗体薬物複合体（ADC）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HER2標的ADC
• CD30標的ADC
• CD19標的ADC
• その他のADC
• 世界の次世代免疫療法市場アンジオテンシン変換酵素（ACE）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん治療におけるACE阻害剤
• その他の適応症に対するACE阻害薬
• 世界の次世代免疫療法市場免疫チェックポイント阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1またはPD-L1阻害剤
• CTLA-4阻害剤
• その他の免疫チェックポイント阻害剤

第7章 地域別・国別分析

• 世界の次世代免疫療法市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の次世代免疫療法市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 次世代免疫療法市場：競合情勢
• 次世代免疫療法市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc（GSK）
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Incyte Corporation
• BioNTech SE
• Xencor Inc.
• Fate Therapeutics Inc.
• Immatics N.V.
• Atara Biotherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 次世代免疫療法市場2029：新たな機会を提供する国
• 次世代免疫療法市場2029：新たな機会を提供するセグメント
• 次世代免疫療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Next-generation immunotherapies are advanced treatments designed to enhance the body's immune system to combat diseases, particularly cancer, with greater precision, efficacy, and safety. These therapies surpass traditional immune-based treatments by utilizing cutting-edge technologies to overcome previous limitations, minimize side effects, and provide long-lasting immune responses.

The primary drug classes in next-generation immunotherapies include monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are lab-engineered proteins that precisely target specific antigens, boosting immune response and treatment effectiveness. These drugs are administered through various routes, such as intravenous, parenteral, intratumoral, subcutaneous, and oral. They are distributed through multiple channels, including hospital pharmacies, clinical pharmacies, and other distribution networks.

The next-generation immunotherapies market research report is one of a series of new reports from The Business Research Company that provides next-generation immunotherapies market statistics, including the next-generation immunotherapies industry global market size, regional shares, competitors with the next-generation immunotherapies market share, detailed next-generation immunotherapies market segments, market trends, and opportunities, and any further data you may need to thrive in the next-generation immunotherapies industry. This next-generation immunotherapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $133.81 billion in 2024 to $150.54 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period can be attributed to the increasing prevalence of oncology, higher investments in research and development, rising government initiatives, increased healthcare expenditures, and the expanding range of indications for immunotherapies.

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $238.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to the rising prevalence of cancer, increasing healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) T-cell therapy, a higher burden of chronic diseases, and expanding research in next-generation drugs. Key trends in the forecast period include a shift toward combination therapies, technological advancements, innovations in therapeutic approaches, progress in personalized medicine, and enhanced regulatory support.

The growing prevalence of cancer is expected to drive the expansion of the next-generation immunotherapies market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing incidence of cancer, including aging populations, lifestyle changes, environmental exposures, and advancements in detection methods. Next-generation immunotherapies offer advanced, targeted treatments that enhance the body's immune response to cancer, providing improved effectiveness, durability, and personalization. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation immunotherapies market.

Leading companies in the next-generation immunotherapies market are focusing on the development of innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is an advanced immunotherapy technique in which a patient's T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India's first CAR T-cell therapy. This treatment targets adult B-cell non-Hodgkin lymphoma by genetically modifying a patient's immune cells to recognize and eliminate cancer cells, offering a highly effective and personalized approach. It presents new hope for patients who have not responded to conventional treatments, with the added benefit of being more cost-effective than similar international options.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition is part of Coherus BioSciences' strategy to expand its immuno-oncology portfolio by developing novel therapies that target the tumor microenvironment to enhance cancer treatment. Surface Oncology Inc., a US-based immuno-oncology company, specializes in next-generation immunotherapies designed to modify the tumor microenvironment for improved treatment outcomes.

Major players in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Next Generation Immunotherapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Immunotherapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation immunotherapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation immunotherapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation immunotherapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Monoclonal Antibodies; Antibody-Drug Conjugates - ADC's; Angiotensin-Converting Enzyme (ACE) Inhibitors; Immune Checkpoint Inhibitors
• 2) By Route Of Administration: Intravenous; Parenteral; Intratumoral; Subcutaneous; Oral
• 3) By Distribution Channel: Hospital Pharmacies; Clinical Pharmacies; Other Distribution channels
• Subsegments:
• 1) By Monoclonal Antibodies: Anti-PD-1 Antibodies; Anti-PD-L1 Antibodies; Anti-CTLA-4 Antibodies; Anti-CD20 Antibodies; Other Monoclonal Antibodies
• 2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs; CD30-targeted ADCs; CD19-targeted ADCs; Other ADCs
• 3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy; ACE Inhibitors For Other Indications
• 4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Other Immune Checkpoint Inhibitors
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next Generation Immunotherapies Market Characteristics

3. Next Generation Immunotherapies Market Trends And Strategies

4. Next Generation Immunotherapies Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Next Generation Immunotherapies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next Generation Immunotherapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next Generation Immunotherapies Market Growth Rate Analysis
• 5.4. Global Next Generation Immunotherapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next Generation Immunotherapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next Generation Immunotherapies Total Addressable Market (TAM)

6. Next Generation Immunotherapies Market Segmentation

• 6.1. Global Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Antibody-Drug Conjugates - ADC's
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Immune Checkpoint Inhibitors
• 6.2. Global Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Parenteral
• Intratumoral
• Subcutaneous
• Oral
• 6.3. Global Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Clinical Pharmacies
• Other Distribution channels
• 6.4. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-PD-1 Antibodies
• Anti-PD-L1 Antibodies
• Anti-CTLA-4 Antibodies
• Anti-CD20 Antibodies
• Other Monoclonal Antibodies
• 6.5. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADC's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HER2-targeted ADCs
• CD30-targeted ADCs
• CD19-targeted ADCs
• Other ADCs
• 6.6. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ACE Inhibitors For Cancer Therapy
• ACE Inhibitors For Other Indications
• 6.7. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Or PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Other Immune Checkpoint Inhibitors

7. Next Generation Immunotherapies Market Regional And Country Analysis

• 7.1. Global Next Generation Immunotherapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next Generation Immunotherapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Immunotherapies Market

• 8.1. Asia-Pacific Next Generation Immunotherapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Immunotherapies Market

• 9.1. China Next Generation Immunotherapies Market Overview
• 9.2. China Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Immunotherapies Market

• 10.1. India Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Immunotherapies Market

• 11.1. Japan Next Generation Immunotherapies Market Overview
• 11.2. Japan Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Immunotherapies Market

• 12.1. Australia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Immunotherapies Market

• 13.1. Indonesia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Immunotherapies Market

• 14.1. South Korea Next Generation Immunotherapies Market Overview
• 14.2. South Korea Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Immunotherapies Market

• 15.1. Western Europe Next Generation Immunotherapies Market Overview
• 15.2. Western Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Immunotherapies Market

• 16.1. UK Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Immunotherapies Market

• 17.1. Germany Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Immunotherapies Market

• 18.1. France Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Immunotherapies Market

• 19.1. Italy Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Immunotherapies Market

• 20.1. Spain Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Immunotherapies Market

• 21.1. Eastern Europe Next Generation Immunotherapies Market Overview
• 21.2. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Immunotherapies Market

• 22.1. Russia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Immunotherapies Market

• 23.1. North America Next Generation Immunotherapies Market Overview
• 23.2. North America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Immunotherapies Market

• 24.1. USA Next Generation Immunotherapies Market Overview
• 24.2. USA Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Immunotherapies Market

• 25.1. Canada Next Generation Immunotherapies Market Overview
• 25.2. Canada Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Immunotherapies Market

• 26.1. South America Next Generation Immunotherapies Market Overview
• 26.2. South America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Immunotherapies Market

• 27.1. Brazil Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Immunotherapies Market

• 28.1. Middle East Next Generation Immunotherapies Market Overview
• 28.2. Middle East Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Immunotherapies Market

• 29.1. Africa Next Generation Immunotherapies Market Overview
• 29.2. Africa Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Immunotherapies Market Competitive Landscape And Company Profiles

• 30.1. Next Generation Immunotherapies Market Competitive Landscape
• 30.2. Next Generation Immunotherapies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Immunotherapies Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc (GSK)
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Incyte Corporation
• 31.11. BioNTech SE
• 31.12. Xencor Inc.
• 31.13. Fate Therapeutics Inc.
• 31.14. Immatics N.V.
• 31.15. Atara Biotherapeutics Inc.

32. Global Next Generation Immunotherapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Immunotherapies Market

34. Recent Developments In The Next Generation Immunotherapies Market

35. Next Generation Immunotherapies Market High Potential Countries, Segments and Strategies

• 35.1 Next Generation Immunotherapies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next Generation Immunotherapies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next Generation Immunotherapies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer